Mirum Pharmaceuticals, Inc. (MIRM) Stock Ticker
MIRM right now
Market factors today
Unlock the full MIRM picture
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM stock facts
| Ticker symbol | MIRM |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.5B |
| CEO | Christopher Peetz |
| Employees | 433 |
| Headquarters | Foster City, CA, US |
| IPO date | 2019-07-18 |
| Website | www.mirumpharma.com |
What you can see for MIRM on Tickr
Live MIRM price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MIRM report.
Rankings
FAQ
What is the ticker symbol for Mirum Pharmaceuticals, Inc.?
The ticker symbol for Mirum Pharmaceuticals, Inc. is MIRM, listed on the NASDAQ Global Market.
What is MIRM?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing…